Mesa, Arizona, 85204, USA

Follow us :
Login
au
10.33826/ijmras/v04i12.2

A PREFORMULATION PROBING OF LEVOTHYROXINE

Abstract

Levothyroxine therapy is given when deficient in the thyroid hormone is found in the human body. Many circumstances physiological or quasi-physiological or clear pathologically, can modify the absorption of levothyroxine in the human body. Levothyroxine intake may actually vary by age and patient compliance, fasting, consumption of certain foods from (fibre, grapes, soybeans, papaya, coffee, etc.) or some medicines (proton pump inhibitors, antacids, sucralfate, etc.) Cetera). In addition, there can be many gastrointestinal illnesses, including conditions and illnesses that disrupt the integrity of the intestinal barrier. Anything that affects stomach acid can alter the bioavailability of levothyroxine. Because it's the huge widespread prevalence of thyroid disease, large many patients face such problems. Therefore, forming the new levothyroxine oral preparations other than solid tablets represent an interesting therapeutic approach at the same time, simple and potent to face this problem. Recently, two different levothyroxine were introduced formulations are proposed: liquid and soft gel formulations. Such prescriptions are innovative and effective an inexpensive therapeutic approach for patients with hypothyroidism with mal-absorption problems levothyroxine. (44)

Keywords
  • Levo-thyroxine; Absorption; Mal-absorption; Liquid formulation; pre-formulating
References
  • HAYS MT. Localization of human thyroxine absorption. Thyroid 1991; 1: 241-248.
  • HAYS MT. Thyroid hormone and the gut. Endocrine Res 1988; 14: 203-224.
  • LIWANPO L, HERSHMAN JM. Conditions and drugs interfere with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009;
  • : 781-792.
  • JOHN-KALARICKAL J, PEARLMAN G, CARLSON HE. New medications which decrease levothyroxine absorption. Thyroid 2007; 17: 763-
  • CENTANNI M, GARGANO L, CANETTIERI G, VICECONTI N, FRANCHI A, DELLE FAVE G, ANNIBALE B. Thyroxine in goiter, Helicobacter
  • pylori infection, and chronic gastritis. N Engl J Med 2006; 354: 1787-1795.
  • SACHMECHI I, REICH DM, ANINYEI M, WIBOWO F, GUPTA G, KIM PJ. Effect of proton pump inhibitors on serum thyroid-stimulating
  • hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocrine Pract 2007; 13: 345- 349.
  • BENVENGA S, BARTOLONE L, SQUADRITO S, LO GIUDICE F, TRIMARCHI F. Delayed intestinal absorption of levothyroxine. Thyroid
  • ; 5: 249-253.
  • WENZEL KW, KIRSCHSIEPER HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26: 1-8.
  • READ DG, HAYS MT, HERSHMAN JM. Absorption of oral thyroxine in hypothyroid and normal man. J Clin Endocrinol Metab 1970; 30:
  • -799.
  • NICOLOFF JT, LOW JC, DUSSAULT JH, FISHER DA. Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover
  • kinetics in man. J Clin Invest 1972; 51: 473-483.
  • MOL JA, VISSER TJ. Rapid and selective inner ring deiodination of thyroxine sulfate by rat liver deiodinase. Endocrinology 1985; 117:
  • -12.
  • BALSAM A, SEXTON F, BORGES M, INGBAR SH. Formation of diiodotyrosine from thyroxine. Ether-link cleavage, an alternate
  • pathway of thyroxine metabolism. J Clin Invest 1983; 72: 1234-1245.
  • PITTMAN CS, CHAMBERS JB JR, READ VH. The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man. J Clin
  • Invest 1971; 50: 1187- 1196.
  • ROBBINS J. Factors altering thyroid hormone metabolism. Environ Health Perspect 1981; 38: 65-70.
  • ENGLER D, MERKELBACH U, STEIGER G, BURGER AG. The mono deiodination of tri iodo thyronine and reverse triiodothyronine in
  • man: a quantitative evaluation of the pathway by the use of turnover rate techniques. J Clin Endocrinol Metab 1984; 58: 49- 61.
  • UTIGER RD. Serum triiodothyronine in man. Annu Rev Med 1974; 25: 289-302.
  • BRAVERMAN LE, VAGENAKIS A, DOWNS P, FOSTER AE, STERLING K, INGBAR SH. Effects of replacement doses of sodium L-thyroxine
  • on the peripheral metabolism of thyroxine and triiodothyronine in man. J Clin Invest 1973; 52: 1010-1017.
  • BENVENGA S, GREGG RE, ROBBINS J. Binding of thyroid hormones to human plasma lipoproteins. JClin Endocrinol Metab 1988; 67:
  • -16.
  • BACH-HUYNH TG, NAYAK B, LOH J, SOLD IN S, JONKLAAS J. Timing of levothyroxine administration affects serum thyrotropin
  • concentration. J Clin Endocrinol Metab 2009; 94: 3905-3912.
  • BOLK N, VISSER TJ, NIJMAN J, JONGSTE IJ, TIJSSEN JG, BERGHOUT A. Effects of evening vs morning levothyroxine intake: a
  • randomized double-blind crossover trial. Arch Intern Med 2010; 170: 1996- 2003.
  • VITA R, SARACENO G, TRIMARCHI F, BENVENGA S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4
  • malabsorption by coffee was observed with traditional tablet formulations. Endocrine 2013; 43: 154-160.
  • CHIU AC, SHERMAN SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 1998; 8: 667-671.
  • DIANA L, MARINI S, MARIOTTI S. Ingestion of large amounts of papaya fruit and impaired effectiveness of levothyroxine therapy.
  • Endocr Pract 2012; 18: 98-100.
  • LILJA JJ, LAITINEN K, NEUVONEN PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 2005; 60: 337-
  • BERNAREGGI A, GRATA E, PINORINI MT, CONTI A. Oral liquid formulation of levothyroxine is stable in breakfast beverages and may
  • improve thyroid patient compliance. Pharmaceutics 2013; 5: 621- 633.
  • LIEL Y, SPERBER AD, SHANY S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med 1994; 97: 363-
  • SPERBER AD, LIEL Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch
  • Intern Med 1992; 152: 183-184.
  • SHERMAN SI, TIELENS ET, LADENSON PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 1994; 96: 531-535.
  • CAMPBELL JA, SCHMIDT BA, BANTLE JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med 1994; 121: 152.
  • CAMPBELL NR, HASINOFF BB, STATES H, RAO B, WONG NC. Ferrous sulfate reduces thyroxine efficacy in patients with
  • hypothyroidism. Ann Intern Med 1992; 117: 1010-1013.
  • SINGH N, SINGH PN, HERSHMAN JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000; 283: 2822-2825.
  • WEITZMAN SP, GINSBURG KC, CARLSON HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of
  • levothyroxine. Thyroid 2009; 19: 77-79.
  • TAKASU N, TAKARA M, KOMIYA I. Rifampin-induced hypothyroidism in patients with Hashimoto's thyroiditis. N Engl J Med 2005; 352:
  • -519.
  • BENEDETTI MS, WHOMSLEY R, BALTES E, TONNER F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans:
  • involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005; 61: 863-872.
  • SHERMAN SI, WIRTH LJ, DROZ JP, HOFMANN M, BASTHOLT L, MARTINS RG, LICITRA L, ESCHENBERG MJ,SUN YN, JUAN T, STEPAN DE,
  • SCHLUMBERGER MJ. Motesanib di-phosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
  • DE FILIPPO C, CAVALIERI D, DI PAOLA M, RAMAZZOTTI M, POULLET JB, MASSART S, COLLINI S, PIERACCINI G, LIONETTI P. Impact of
  • diet in shaping gut micro biot a revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A
  • ; 107: 14691-14696.
  • LAURITANO EC, BILOTTA AL, GABRIELLI M, SCARPELLINI E, LUPASCU A, LAGINESTRA A, NOVI M, SOTTILI S, SERRICCHIO M,
  • CAMMAROTA G, GASBARRINI G, PONTECORVI A, GASBARRINI A. Association between hypothyroidism and small intestinal bacterial
  • overgrowth. J Clin Endocrinol Metab 2007; 92: 4180-4184.
  • LIN HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858.
  • VITA R, BENVENGA S. Tablet Levothyroxine (L-T4) malabsorption induced by proton pump inhibitor: a problem that was solved by
  • switching to L-T4 in a soft gel capsule. Endo cr Pract 2013 Nov 18: 1-11.
  • YUE CS, SCARSI C, DUCHARME MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other
  • available dosage forms. Arzneimittelforschung 2012; 62: 631-636.
  • CASSIO A, MONTI S, RIZZELLO A, BETTOCCHI I, BARONIO F, D'ADDABBO G, BAL MO, BALSAMO A. Comparison between liquid and
  • tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr 2013; 162: 1264-1269, 1269.e1-2.
  • PIROLA I, FORMENTI AM, GANDOSSI E, MITTEMPERGHER F, CASELLA C, AGOSTI B, CAPPELLI C. Oral liquid L-thyroxine (L-t4) may be
  • better absorbed compared to LT4 tablets following bariatric surgery. Obesity Surg 2013; 23: 1493-1496.
  • CAPPELLI C, PIROLA I, GANDOSSI E, FORMENTI A, CASTELLANO M. Oral liquid levothyroxine treatment at breakfast: a mistake? Eur J
  • Endocrinol 2013; 170: 95-99.
  • Source https://www.europeanreview.org/wp/wp-content/uploads/451-4561.pdf

Authors

  • Anirban Bhattacharjee
    Affiliation:- a:1:{s:5:"en_US";s:73:"Faculty at department of pharmaceutics in university of Dhaka Bangladesh.";}
  • Prof Rajeev
    Affiliation:- Faculty at department of pharmaceutics in university of Dhaka Bangladesh

How to Cite

Bhattacharjee, A., & Shah, P. R. . (2021). A PREFORMULATION PROBING OF LEVOTHYROXINE. International Journal of Multidisciplinary Research and Studies, 4(12), 01–08. https://doi.org/10.33826/ijmras/v04i12.2

Download Citation


Downloads

Download data is not yet available.